Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MIRA Pharmaceuticals, Inc. - Common Stock (NQ: MIRA ) 1.180 -0.020 (-1.67%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 514,818 Open 1.190 Bid (Size) 1.170 (8) Ask (Size) 1.180 (17) Prev. Close 1.200 Today's Range 1.100 - 1.200 52wk Range 0.5100 - 5.010 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development December 19, 2024 Via ACCESSWIRE EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment December 19, 2024 MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies. Via Benzinga Exposures Product Safety Performance YTD -0.84% -0.84% 1 Month -7.09% -7.09% 3 Month +1.72% +1.72% 6 Month +85.24% +85.24% 1 Year +7.27% +7.27% More News Read More MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End December 10, 2024 Via ACCESSWIRE EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain December 10, 2024 Via Benzinga MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site November 20, 2024 Via ACCESSWIRE MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain October 28, 2024 Via Benzinga Peering Into Mira Pharmaceuticals's Recent Short Interest September 11, 2024 Via Benzinga MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study August 26, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's Pre-Market Session October 28, 2024 Via Benzinga MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain October 28, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Friday's After-Market Session October 25, 2024 Via Benzinga MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study October 21, 2024 Via ACCESSWIRE Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game October 03, 2024 Via News Direct Topics Cannabis Exposures Cannabis Why Mira Shares Are Trading Higher Today September 27, 2024 Via Benzinga MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 September 27, 2024 Via ACCESSWIRE MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 September 19, 2024 Via News Direct MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 September 18, 2024 Via ACCESSWIRE MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA September 11, 2024 Via ACCESSWIRE The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End August 27, 2024 Via News Direct MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies August 26, 2024 Via Benzinga Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket August 26, 2024 Via Benzinga Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday August 26, 2024 Via Benzinga MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End August 19, 2024 Via ACCESSWIRE MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024 August 13, 2024 Via InvestorPlace MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor August 12, 2024 Via ACCESSWIRE Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
